What happened
- UTHealth Houston researchers published in Neurology a study in which adults 65 and older who got the high-dose flu vaccine were less likely to develop Alzheimer’s than those given the standard dose.
- ScienceDaily circulated it on 7 November 2026, with a headline citing about 55% lower risk.
- The study grew out of an unexpected conversation between a UTHealth Houston physician and public health officials.
- Paul Schulz, professor of neurology at McGovern Medical School, had found in a 2022 study that flu vaccination was associated with less Alzheimer’s among people over 65.
Why it matters
If vaccine strength affects risk, the effect might not be only against the virus but on general immune response, a hypothesis medicine is exploring: some vaccines may modulate inflammatory processes tied to neurodegeneration. At scale, more than 7 million Americans 65 and older lived with Alzheimer’s in 2025, about one in nine, and the figure is projected to more than double by 2050. A simple, already available measure draws interest.
The number
About 55% lower risk. The reduction associated with high versus standard dose, per ScienceDaily’s headline; an observational association, not proof of cause.
Context
An observational study compares groups that already received one vaccine or the other and does not randomize, so other differences between recipients may explain part of the effect. The text read does not detail how age, other illnesses or access to care were controlled. The result points to an association worth controlled trials, not a reason to choose the high dose to prevent Alzheimer’s. Flu vaccination should follow current guidelines. Related coverage: Alcohol makes the liver send inflammatory signals to the brain in Alzheimer mice, Alzheimer-type changes in 14% of ALS patients are linked to shorter survival, A PET scan with a labelled amino acid detects 91% of glioblastoma, against 53% for MRI, More free DNA in the blood improves early cancer detection instead of diluting it.
Studies comparing two vaccines already given can be affected by who receives each one. If the high dose is offered more often to people who attend regular check-ups, that alone could reduce late diagnoses or raise early ones and skew the comparison. Researchers usually adjust for age, sex and prior illness, but a margin of unmeasured factors always remains that can explain part of the result.
What’s next
- Randomized trials are needed to confirm whether the high dose lowers risk.
- Other studies can repeat the analysis in different populations.
- Teams will explore immune mechanisms that could explain the link.
Bottom line
A strong association in a disease with no simple treatment deserves rigorous follow-up. It does not yet deserve changing medical advice.
Sources
- ScienceDaily, “Stronger flu shot linked to nearly 55% lower Alzheimer’s risk”, 7 November 2026, on a UTHealth Houston study in Neurology. The original paper was not read.
- Cover image: autor no indicado, CC BY 4.0, via Wikimedia Commons
Edited by Rodrigo Cornejo. How we select and verify: who writes these notes.
